Schrenk D, Dekant W
Institut für Toxikologie, Universität-Würzburg, FRG.
Carcinogenesis. 1989 Jun;10(6):1139-41. doi: 10.1093/carcin/10.6.1139.
The covalent binding of [14C]hexachlorobutadiene (HCBD) metabolites to DNA was investigated in mouse liver and kidney after application of a single oral dose of 30 mg/kg. A low level of binding of [14C]HCBD metabolites to nuclear DNA (nDNA) from kidney with a covalent binding index (CBI) of 27 was detectable, whereas nDNA from liver did not retain radioactivity significantly exceeding background activity (background CBInDNA = 6 and CBImtDNA = 60). Considerably higher binding of metabolites to mitochondrial DNA (mtDNA) from liver (CBI = 500) and kidney (CBI = 7500) could be demonstrated. Enzymatic hydrolysis followed by HPLC fractionation of mtDNA from mouse kidney revealed the presence of three radioactive compounds which may represent DNA bases altered by HCBD metabolites. The observed binding of HCBD metabolites to DNA constituents in vivo suggests that genotoxic mechanisms are operative in initiating HCBD nephrocarcinogenesis.
在单次口服剂量为30 mg/kg的[14C]六氯丁二烯(HCBD)后,研究了其代谢产物与小鼠肝脏和肾脏中DNA的共价结合情况。可检测到[14C] HCBD代谢产物与肾脏核DNA(nDNA)有低水平的结合,共价结合指数(CBI)为27,而肝脏的nDNA未保留明显超过背景活性的放射性(背景CBInDNA = 6,CBImtDNA = 60)。可以证明代谢产物与肝脏(CBI = 500)和肾脏(CBI = 7500)的线粒体DNA(mtDNA)有相当高的结合。对小鼠肾脏的mtDNA进行酶解,然后用HPLC分离,发现存在三种放射性化合物,它们可能代表被HCBD代谢产物改变的DNA碱基。观察到的HCBD代谢产物在体内与DNA成分的结合表明,遗传毒性机制在引发HCBD肾致癌过程中起作用。